The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | Considering enrolment in clinical trials for patients with amyloidosis
Victor Jimenez Zepeda, MD, PhD, University of Calgary, Calgary, Canada, briefly discusses the importance of discussing clinical trial enrolment with patients with amyloidosis. Ongoing trials aim to improve standard of care regimens; for example, by adding monoclonal antibodies, and enrolling patients in these trials may improve their clinical outcomes. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
